MBRX vs. MNPR, MTEM, AEZS, ELAB, AKTX, GRTX, GHSI, IMNN, ERNA, and MIRA
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Monopar Therapeutics (MNPR), Molecular Templates (MTEM), Aeterna Zentaris (AEZS), Elevai Labs (ELAB), Akari Therapeutics (AKTX), Galera Therapeutics (GRTX), Guardion Health Sciences (GHSI), Imunon (IMNN), Eterna Therapeutics (ERNA), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, community ranking, valuation, earnings and profitability.
In the previous week, Moleculin Biotech had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 3 mentions for Moleculin Biotech and 2 mentions for Monopar Therapeutics. Moleculin Biotech's average media sentiment score of 0.00 equaled Monopar Therapeutics'average media sentiment score.
Moleculin Biotech received 189 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 70.37% of users gave Monopar Therapeutics an outperform vote while only 53.41% of users gave Moleculin Biotech an outperform vote.
Monopar Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Monopar Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.
1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 41.6% of Monopar Therapeutics shares are held by company insiders. Comparatively, 6.7% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Monopar Therapeutics' return on equity of -80.91% beat Moleculin Biotech's return on equity.
Monopar Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 175.03%. Moleculin Biotech has a consensus target price of $35.00, indicating a potential upside of 597.21%. Given Monopar Therapeutics' higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Monopar Therapeutics.
Summary
Moleculin Biotech beats Monopar Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
